Full Press Release Details
0001434265--12-312023FYfalseP30D0.02250P4YP3YP4YP1YGenmab A/S6-K2023-12-310001434265gmab:EquipmentFurnitureAndFixturesMemberifrs-full:TopOfRangeMember2023-01-012023-12-310001434265gmab:EquipmentFurnitureAndFixturesMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310001434265ifrs-full:LeaseholdImprovementsMember2023-01-012023-12-310001434265ifrs-full:ComputerEquipmentMember2023-01-012023-12-310001434265gmab:IfrsUnitedStatesMember2023-12-310001434265gmab:IfrsNetherlandsMember2023-12-310001434265ifrs-full:NotLaterThanOneYearMember2023-12-310001434265ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2023-12-310001434265ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2023-12-310001434265ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2022-12-310001434265ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2022-12-310001434265ifrs-full:NotLaterThanOneYearMember2021-12-310001434265ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2021-12-310001434265ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2021-12-310001434265ifrs-full:LaterThanFiveYearsMember2021-12-310001434265gmab:OtherInvestmentMember2023-01-012023-12-310001434265gmab:AgreementsWithAbbvieMembergmab:DevelopmentRegulatoryAndSalesMilestoneMemberifrs-full:TopOfRangeMember2020-06-100001434265gmab:AgreementsWithAbbvieMembergmab:DevelopmentRegulatoryAndSalesMilestoneMembergmab:SuccessOfAllFourNextGenerationAntibodyProductCandidatesDevelopedMember2020-06-100001434265gmab:AgreementsWithAbbvieMembergmab:DevelopmentRegulatoryAndSalesMilestoneMembergmab:ClinicalDevelopmentAndCommercialSuccessAcrossAllThreeProgramsMember2020-06-100001434265gmab:TepezzaMember2023-01-012023-12-310001434265gmab:RoyaltiesRevenueMember2023-01-012023-12-310001434265gmab:ReimbursementIncomeMember2023-01-012023-12-310001434265gmab:PfizerMember2023-01-012023-12-310001434265gmab:OtherRoyaltyProductMember2023-01-012023-12-310001434265gmab:NovartisMember2023-01-012023-12-310001434265gmab:NetProductSalesMember2023-01-012023-12-310001434265gmab:MilestonePaymentsRevenueMember2023-01-012023-12-310001434265gmab:KesimptaMember2023-01-012023-12-310001434265gmab:ExcludingNetProductSalesMember2023-01-012023-12-310001434265gmab:DarzalexMember2023-01-012023-12-310001434265gmab:CollaborationRevenueMember2023-01-012023-12-310001434265gmab:AgreementsWithRocheMember2023-01-012023-12-310001434265gmab:AgreementsWithAbbvieMember2023-01-012023-12-310001434265gmab:TepezzaMember2022-01-012022-12-310001434265gmab:RoyaltiesRevenueMember2022-01-012022-12-310001434265gmab:ReimbursementIncomeMember2022-01-012022-12-310001434265gmab:PfizerMember2022-01-012022-12-310001434265gmab:OtherRoyaltyProductMember2022-01-012022-12-310001434265gmab:OtherCollaborationPartnersMember2022-01-012022-12-310001434265gmab:NovartisMember2022-01-012022-12-310001434265gmab:MilestonePaymentsRevenueMember2022-01-012022-12-310001434265gmab:LicenseFeesMember2022-01-012022-12-310001434265gmab:KesimptaMember2022-01-012022-12-310001434265gmab:DarzalexMember2022-01-012022-12-310001434265gmab:CollaborationRevenueMember2022-01-012022-12-310001434265gmab:AgreementsWithRocheMember2022-01-012022-12-310001434265gmab:AgreementsWithJanssenMember2022-01-012022-12-310001434265gmab:AgreementsWithBointechMember2022-01-012022-12-310001434265gmab:AgreementsWithAbbvieMember2022-01-012022-12-310001434265gmab:TepezzaMember2021-01-012021-12-310001434265gmab:RoyaltiesRevenueMember2021-01-012021-12-310001434265gmab:ReimbursementIncomeMember2021-01-012021-12-310001434265gmab:PfizerMember2021-01-012021-12-310001434265gmab:OtherRoyaltyProductMember2021-01-012021-12-310001434265gmab:NovartisMember2021-01-012021-12-310001434265gmab:MilestonePaymentsRevenueMember2021-01-012021-12-310001434265gmab:KesimptaMember2021-01-012021-12-310001434265gmab:DarzalexMember2021-01-012021-12-310001434265gmab:CollaborationRevenueMember2021-01-012021-12-310001434265gmab:AgreementsWithRocheMember2021-01-012021-12-310001434265gmab:AgreementsWithJanssenMember2021-01-012021-12-310001434265gmab:AgreementsWithBointechMember2021-01-012021-12-310001434265gmab:AgreementsWithAbbvieMember2021-01-012021-12-310001434265country:US2023-01-012023-12-310001434265country:JP2023-01-012023-12-310001434265country:DK2023-01-012023-12-310001434265country:DK2022-01-012022-12-310001434265country:DK2021-01-012021-12-310001434265gmab:AgreementsWithAbbvieMember2020-01-012020-12-310001434265gmab:OtherInvestmentMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-01-012022-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2023-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-12-310001434265ifrs-full:GrossCarryingAmountMembergmab:EquipmentFurnitureAndFixturesMember2023-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember2023-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembergmab:EquipmentFurnitureAndFixturesMember2023-12-310001434265ifrs-full:LeaseholdImprovementsMember2023-12-310001434265ifrs-full:ConstructionInProgressMember2023-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310001434265gmab:EquipmentFurnitureAndFixturesMember2023-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2022-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-12-310001434265ifrs-full:GrossCarryingAmountMembergmab:EquipmentFurnitureAndFixturesMember2022-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember2022-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembergmab:EquipmentFurnitureAndFixturesMember2022-12-310001434265ifrs-full:LeaseholdImprovementsMember2022-12-310001434265ifrs-full:GrossCarryingAmountMember2022-12-310001434265ifrs-full:ConstructionInProgressMember2022-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310001434265gmab:EquipmentFurnitureAndFixturesMember2022-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2021-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2021-12-310001434265ifrs-full:GrossCarryingAmountMembergmab:EquipmentFurnitureAndFixturesMember2021-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember2021-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembergmab:EquipmentFurnitureAndFixturesMember2021-12-310001434265ifrs-full:GrossCarryingAmountMember2021-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2023-12-310001434265gmab:ExecutiveManagementMembergmab:IfrsRestrictedStockUnitsRSUsMember2023-12-310001434265gmab:EmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2023-12-310001434265gmab:BoardOfDirectorsMembergmab:IfrsRestrictedStockUnitsRSUsMember2023-12-310001434265gmab:IfrsRestrictedStockUnitsRSUsMember2023-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2022-12-310001434265gmab:ExecutiveManagementMembergmab:IfrsRestrictedStockUnitsRSUsMember2022-12-310001434265gmab:EmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2022-12-310001434265gmab:BoardOfDirectorsMembergmab:IfrsRestrictedStockUnitsRSUsMember2022-12-310001434265gmab:IfrsRestrictedStockUnitsRSUsMember2022-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2021-12-310001434265gmab:ExecutiveManagementMembergmab:IfrsRestrictedStockUnitsRSUsMember2021-12-310001434265gmab:EmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2021-12-310001434265gmab:BoardOfDirectorsMembergmab:IfrsRestrictedStockUnitsRSUsMember2021-12-310001434265gmab:IfrsRestrictedStockUnitsRSUsMember2021-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2020-12-310001434265gmab:ExecutiveManagementMembergmab:IfrsRestrictedStockUnitsRSUsMember2020-12-310001434265gmab:EmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2020-12-310001434265gmab:BoardOfDirectorsMembergmab:IfrsRestrictedStockUnitsRSUsMember2020-12-310001434265gmab:IfrsRestrictedStockUnitsRSUsMember2020-12-310001434265country:US2023-12-310001434265country:NL2023-12-310001434265country:JP2023-12-310001434265country:DK2023-12-310001434265country:US2022-12-310001434265country:NL2022-12-310001434265country:JP2022-12-310001434265country:DK2022-12-310001434265country:US2021-12-310001434265country:NL2021-12-310001434265country:JP2021-12-310001434265country:DK2021-12-310001434265ifrs-full:TradingEquitySecuritiesMember2023-12-310001434265ifrs-full:InvestmentFundsMember2023-12-310001434265ifrs-full:TradingEquitySecuritiesMember2022-12-310001434265ifrs-full:InvestmentFundsMember2022-12-310001434265ifrs-full:AccumulatedImpairmentMember2023-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LicencesAndFranchisesMember2023-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LicencesAndFranchisesMember2023-12-310001434265ifrs-full:LicencesAndFranchisesMember2023-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LicencesAndFranchisesMember2022-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LicencesAndFranchisesMember2022-12-310001434265ifrs-full:LicencesAndFranchisesMember2022-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LicencesAndFranchisesMember2021-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LicencesAndFranchisesMember2021-12-310001434265ifrs-full:SharePremiumMember2023-01-012023-12-310001434265ifrs-full:SharePremiumMember2022-01-012022-12-310001434265ifrs-full:SharePremiumMember2021-01-012021-12-310001434265gmab:OtherInvestmentMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-01-012023-12-310001434265ifrs-full:GrossCarryingAmountMember2023-12-310001434265ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberifrs-full:LeaseLiabilitiesMember2023-12-310001434265ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembergmab:OtherPayablesMember2023-12-310001434265ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberifrs-full:LeaseLiabilitiesMember2022-12-310001434265ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMembergmab:OtherPayablesMember2022-12-310001434265gmab:OtherInvestmentMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310001434265gmab:OtherInvestmentMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310001434265gmab:MarketableSecuritiesMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2023-12-310001434265ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembergmab:OtherInvestmentMember2023-12-310001434265ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembergmab:MarketableSecuritiesMember2023-12-310001434265ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembergmab:ReceivablesExPrepaymentsMember2023-12-310001434265ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembergmab:IfrsCashAndCashEquivalentsMember2023-12-310001434265gmab:OtherInvestmentMemberifrs-full:AtFairValueMember2023-12-310001434265gmab:MarketableSecuritiesMemberifrs-full:AtFairValueMember2023-12-310001434265gmab:OtherInvestmentMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310001434265gmab:OtherInvestmentMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310001434265gmab:MarketableSecuritiesMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-12-310001434265ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembergmab:OtherInvestmentMember2022-12-310001434265ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMembergmab:MarketableSecuritiesMember2022-12-310001434265ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembergmab:ReceivablesExPrepaymentsMember2022-12-310001434265ifrs-full:FinancialAssetsAtAmortisedCostCategoryMembergmab:IfrsCashAndCashEquivalentsMember2022-12-310001434265gmab:OtherInvestmentMemberifrs-full:AtFairValueMember2022-12-310001434265gmab:MarketableSecuritiesMemberifrs-full:AtFairValueMember2022-12-310001434265gmab:OtherInvestmentMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-12-310001434265ifrs-full:SharePremiumMember2023-12-310001434265ifrs-full:RetainedEarningsMember2023-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001434265ifrs-full:IssuedCapitalMember2023-12-310001434265ifrs-full:SharePremiumMember2022-12-310001434265ifrs-full:RetainedEarningsMember2022-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-12-310001434265ifrs-full:IssuedCapitalMember2022-12-310001434265ifrs-full:SharePremiumMember2021-12-310001434265ifrs-full:RetainedEarningsMember2021-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001434265ifrs-full:IssuedCapitalMember2021-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember2023-01-012023-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembergmab:EquipmentFurnitureAndFixturesMember2023-01-012023-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-12-310001434265ifrs-full:OtherTemporaryDifferencesMember2023-12-310001434265gmab:ShareBasedInstrumentsMember2023-12-310001434265gmab:DeferredRevenueMember2023-12-310001434265ifrs-full:OtherTemporaryDifferencesMember2022-12-310001434265gmab:ShareBasedInstrumentsMember2022-12-310001434265gmab:DeferredRevenueMember2022-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-01-012023-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-12-310001434265ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember2022-01-012022-12-310001434265ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember2021-01-012021-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LicencesAndFranchisesMember2023-01-012023-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LicencesAndFranchisesMember2022-01-012022-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2023-01-012023-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-01-012023-12-310001434265ifrs-full:GrossCarryingAmountMembergmab:EquipmentFurnitureAndFixturesMember2023-01-012023-12-310001434265ifrs-full:GrossCarryingAmountMember2023-01-012023-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2022-01-012022-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-01-012022-12-310001434265ifrs-full:GrossCarryingAmountMembergmab:EquipmentFurnitureAndFixturesMember2022-01-012022-12-310001434265ifrs-full:GrossCarryingAmountMember2022-01-012022-12-310001434265ifrs-full:GrossCarryingAmountMemberifrs-full:LicencesAndFranchisesMember2023-01-012023-12-310001434265gmab:ExercisePrice962.00Member2023-01-012023-12-310001434265gmab:ExercisePrice3172.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2806.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2698.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2688.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2680.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2661.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2641.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2594.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2585.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2492.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2491.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2408.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2381.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2317.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2175.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2148.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2144Member2023-01-012023-12-310001434265gmab:ExercisePrice2129.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2103.00Member2023-01-012023-12-310001434265gmab:ExercisePrice2070.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1980.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1948.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1615.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1432.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1408.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1402.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1362.50Member2023-01-012023-12-310001434265gmab:ExercisePrice1334.50Member2023-01-012023-12-310001434265gmab:ExercisePrice1210.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1161.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1155.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1147.50Member2023-01-012023-12-310001434265gmab:ExercisePrice1050.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1032.00Member2023-01-012023-12-310001434265gmab:ExercisePrice1025.00Member2023-01-012023-12-310001434265gmab:ExercisePriceTwentyTwoMember2022-01-012022-12-310001434265gmab:ExercisePriceTwentyThreeMember2022-01-012022-12-310001434265gmab:ExercisePriceTwentySixMember2022-01-012022-12-310001434265gmab:ExercisePriceTwentySevenMember2022-01-012022-12-310001434265gmab:ExercisePriceTwentyOneMember2022-01-012022-12-310001434265gmab:ExercisePriceTwentyNineMember2022-01-012022-12-310001434265gmab:ExercisePriceTwentyFourMember2022-01-012022-12-310001434265gmab:ExercisePriceTwentyFiveMember2022-01-012022-12-310001434265gmab:ExercisePriceTwentyEightMember2022-01-012022-12-310001434265gmab:ExercisePriceThirtyTwoMember2022-01-012022-12-310001434265gmab:ExercisePriceThirtyOneMember2022-01-012022-12-310001434265gmab:ExercisePriceThirtyMember2022-01-012022-12-310001434265gmab:ExercisePriceNineteenMember2022-01-012022-12-310001434265gmab:ExercisePrice3172.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2806.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2698.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2641.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2585.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2492.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2408.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2381.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2317.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2175.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2148.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2129.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2103.00Member2022-01-012022-12-310001434265gmab:ExercisePrice2070.00Member2022-01-012022-12-310001434265gmab:ExercisePrice1948.00Member2022-01-012022-12-310001434265gmab:ExercisePrice1770.31Member2022-01-012022-12-310001434265gmab:ExercisePrice1615.00Member2022-01-012022-12-310001434265gmab:ExercisePrice1432.00Member2022-01-012022-12-310001434265gmab:ExercisePrice1427.00Member2022-01-012022-12-310001434265gmab:ExercisePrice1424.00Member2022-01-012022-12-310001434265gmab:ExercisePrice1408.00Member2022-01-012022-12-310001434265gmab:ExercisePrice1402.00Member2022-01-012022-12-310001434265gmab:ExercisePrice1362.50Member2022-01-012022-12-310001434265gmab:AgreementsWithAbbvieMember2020-06-012020-06-300001434265gmab:RestrictedStockUnitsRSUsMember2023-01-012023-12-310001434265gmab:StockRepurchaseFirstAuthorizationMember2022-01-012022-12-310001434265gmab:StockRepurchaseSecondAuthorizationMember2019-01-012019-12-310001434265gmab:StockRepurchaseThirdAuthorizationMember2016-01-012016-12-310001434265srt:ParentCompanyMembergmab:GenmabUsInc.Member2023-01-012023-12-310001434265srt:ParentCompanyMembergmab:GenmabK.k.Member2023-01-012023-12-310001434265srt:ParentCompanyMembergmab:GenmabHoldingB.v.Member2023-01-012023-12-310001434265srt:ParentCompanyMembergmab:GenmabB.v.Member2023-01-012023-12-310001434265srt:ParentCompanyMembergmab:GenmabUsInc.Member2022-01-012022-12-310001434265srt:ParentCompanyMembergmab:GenmabK.k.Member2022-01-012022-12-310001434265srt:ParentCompanyMembergmab:GenmabHoldingB.v.Member2022-01-012022-12-310001434265srt:ParentCompanyMembergmab:GenmabB.v.Member2022-01-012022-12-310001434265gmab:AgreementsWithAbbvieMember2020-07-012020-07-310001434265ifrs-full:TreasurySharesMember2023-12-310001434265ifrs-full:TreasurySharesMember2022-12-310001434265ifrs-full:TreasurySharesMember2021-12-310001434265ifrs-full:TreasurySharesMember2020-12-310001434265gmab:RestrictedStockUnitsRSUsMember2022-01-012022-12-310001434265gmab:RestrictedStockUnitsRSUsMember2021-01-012021-12-310001434265gmab:GmabWarrantsGrantedFromMarchTwoThousandSeventeenUntilFebruaryTwoThousandTwentyOneMember2023-01-012023-12-310001434265gmab:GmabWarrantsGrantedFromAprilTwoThousandTwelveUntilMarchTwoThousandSeventeenMember2023-01-012023-12-310001434265ifrs-full:CurrencyRiskMember2021-01-012021-12-310001434265currency:DKK2022-01-012022-12-310001434265ifrs-full:CurrencyRiskMembercurrency:USD2023-01-012023-12-310001434265ifrs-full:CurrencyRiskMembercurrency:GBP2023-01-012023-12-310001434265ifrs-full:CurrencyRiskMembercurrency:EUR2023-01-012023-12-310001434265ifrs-full:CurrencyRiskMembercurrency:DKK2023-01-012023-12-310001434265ifrs-full:CurrencyRiskMember2023-01-012023-12-310001434265ifrs-full:CurrencyRiskMembercurrency:USD2022-01-012022-12-310001434265ifrs-full:CurrencyRiskMembercurrency:GBP2022-01-012022-12-310001434265ifrs-full:CurrencyRiskMembercurrency:EUR2022-01-012022-12-310001434265ifrs-full:CurrencyRiskMembercurrency:DKK2022-01-012022-12-310001434265ifrs-full:CurrencyRiskMember2022-01-012022-12-310001434265gmab:BoardOfDirectorsMembergmab:IfrsRestrictedStockUnitsRSUsMember2023-01-012023-12-310001434265gmab:ExecutiveManagementMembergmab:IfrsRestrictedStockUnitsRSUsMember2022-01-012022-12-310001434265gmab:ExecutiveManagementMembergmab:IfrsRestrictedStockUnitsRSUsMember2021-01-012021-12-310001434265gmab:ExercisePrice3172.00Member2023-12-310001434265gmab:ExercisePrice2806.00Member2023-12-310001434265gmab:ExercisePrice2698.00Member2023-12-310001434265gmab:ExercisePrice2688.00Member2023-12-310001434265gmab:ExercisePrice2680.00Member2023-12-310001434265gmab:ExercisePrice2661.00Member2023-12-310001434265gmab:ExercisePrice2641.00Member2023-12-310001434265gmab:ExercisePrice2594.00Member2023-12-310001434265gmab:ExercisePrice2585.00Member2023-12-310001434265gmab:ExercisePrice2492.00Member2023-12-310001434265gmab:ExercisePrice2491.00Member2023-12-310001434265gmab:ExercisePrice2408.00Member2023-12-310001434265gmab:ExercisePrice2175.00Member2023-12-310001434265gmab:ExercisePrice2148.00Member2023-12-310001434265gmab:ExercisePrice2144Member2023-12-310001434265gmab:ExercisePrice2129.00Member2023-12-310001434265gmab:ExercisePrice2103.00Member2023-12-310001434265gmab:ExercisePrice2070.00Member2023-12-310001434265gmab:ExercisePrice3172.00Member2022-12-310001434265gmab:ExercisePrice2806.00Member2022-12-310001434265gmab:ExercisePrice2698.00Member2022-12-310001434265gmab:ExercisePrice2641.00Member2022-12-310001434265gmab:ExercisePrice2585.00Member2022-12-310001434265gmab:ExercisePrice2492.00Member2022-12-310001434265gmab:ExercisePrice2408.00Member2022-12-310001434265gmab:ExercisePrice2381.00Member2022-12-310001434265gmab:ExercisePrice2317.00Member2022-12-310001434265gmab:ExercisePrice2175.00Member2022-12-310001434265gmab:ExercisePrice2148.00Member2022-12-310001434265gmab:ExercisePrice2129.00Member2022-12-310001434265gmab:ExercisePrice2103.00Member2022-12-310001434265gmab:ExercisePrice2070.00Member2022-12-310001434265gmab:ExercisePrice1948.00Member2022-12-310001434265gmab:ExercisePrice1362.50Member2022-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMember2020-12-310001434265gmab:ExecutiveManagementMember2020-12-310001434265gmab:EmployeesMember2020-12-310001434265gmab:BoardOfDirectorsMember2020-12-310001434265gmab:StockRepurchaseSecondAuthorizationMember2023-12-310001434265gmab:StockRepurchaseFirstAuthorizationMember2023-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMember2023-12-310001434265gmab:ExercisePrice962.00Member2023-12-310001434265gmab:ExercisePrice2381.00Member2023-12-310001434265gmab:ExercisePrice2317.00Member2023-12-310001434265gmab:ExercisePrice1980.00Member2023-12-310001434265gmab:ExercisePrice1948.00Member2023-12-310001434265gmab:ExercisePrice1615.00Member2023-12-310001434265gmab:ExercisePrice1432.00Member2023-12-310001434265gmab:ExercisePrice1408.00Member2023-12-310001434265gmab:ExercisePrice1402.00Member2023-12-310001434265gmab:ExercisePrice1362.50Member2023-12-310001434265gmab:ExercisePrice1334.50Member2023-12-310001434265gmab:ExercisePrice1210.00Member2023-12-310001434265gmab:ExercisePrice1161.00Member2023-12-310001434265gmab:ExercisePrice1155.00Member2023-12-310001434265gmab:ExercisePrice1147.50Member2023-12-310001434265gmab:ExercisePrice1050.00Member2023-12-310001434265gmab:ExercisePrice1032.00Member2023-12-310001434265gmab:ExercisePrice1025.00Member2023-12-310001434265gmab:ExecutiveManagementMember2023-12-310001434265gmab:EmployeesMember2023-12-310001434265gmab:BoardOfDirectorsMember2023-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMember2022-12-310001434265gmab:ExercisePriceTwentyTwoMember2022-12-310001434265gmab:ExercisePriceTwentyThreeMember2022-12-310001434265gmab:ExercisePriceTwentySixMember2022-12-310001434265gmab:ExercisePriceTwentySevenMember2022-12-310001434265gmab:ExercisePriceTwentyOneMember2022-12-310001434265gmab:ExercisePriceTwentyNineMember2022-12-310001434265gmab:ExercisePriceTwentyFourMember2022-12-310001434265gmab:ExercisePriceTwentyFiveMember2022-12-310001434265gmab:ExercisePriceTwentyEightMember2022-12-310001434265gmab:ExercisePriceThirtyTwoMember2022-12-310001434265gmab:ExercisePriceThirtyOneMember2022-12-310001434265gmab:ExercisePriceThirtyMember2022-12-310001434265gmab:ExercisePriceNineteenMember2022-12-310001434265gmab:ExercisePrice1770.31Member2022-12-310001434265gmab:ExercisePrice1615.00Member2022-12-310001434265gmab:ExercisePrice1432.00Member2022-12-310001434265gmab:ExercisePrice1427.00Member2022-12-310001434265gmab:ExercisePrice1424.00Member2022-12-310001434265gmab:ExercisePrice1408.00Member2022-12-310001434265gmab:ExercisePrice1402.00Member2022-12-310001434265gmab:ExecutiveManagementMember2022-12-310001434265gmab:EmployeesMember2022-12-310001434265gmab:BoardOfDirectorsMember2022-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMember2021-12-310001434265gmab:ExecutiveManagementMember2021-12-310001434265gmab:EmployeesMember2021-12-310001434265gmab:BoardOfDirectorsMember2021-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2023-01-012023-12-310001434265gmab:ExecutiveManagementMembergmab:IfrsRestrictedStockUnitsRSUsMember2023-01-012023-12-310001434265gmab:EmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2023-01-012023-12-310001434265gmab:IfrsRestrictedStockUnitsRSUsMember2023-01-012023-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMember2023-01-012023-12-310001434265gmab:EmployeesMember2023-01-012023-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2022-01-012022-12-310001434265gmab:EmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2022-01-012022-12-310001434265gmab:BoardOfDirectorsMembergmab:IfrsRestrictedStockUnitsRSUsMember2022-01-012022-12-310001434265gmab:IfrsRestrictedStockUnitsRSUsMember2022-01-012022-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMember2022-01-012022-12-310001434265gmab:EmployeesMember2022-01-012022-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2021-01-012021-12-310001434265gmab:EmployeesMembergmab:IfrsRestrictedStockUnitsRSUsMember2021-01-012021-12-310001434265gmab:BoardOfDirectorsMembergmab:IfrsRestrictedStockUnitsRSUsMember2021-01-012021-12-310001434265gmab:IfrsRestrictedStockUnitsRSUsMember2021-01-012021-12-310001434265gmab:FormerMemberOfBoardOfDirectorsAndEmployeesMember2021-01-012021-12-310001434265gmab:EmployeesMember2021-01-012021-12-310001434265gmab:StockRepurchaseFirstAuthorizationMember2022-12-310001434265gmab:StockRepurchaseSecondAuthorizationMember2019-12-310001434265gmab:StockRepurchaseThirdAuthorizationMember2016-12-310001434265gmab:AgreementWithJanssenDuobodyMember2023-12-310001434265gmab:ExecutiveManagementMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310001434265gmab:AgreementsWithAbbvieMemberifrs-full:TopOfRangeMember2020-06-100001434265gmab:AgreementsWithAbbvieMember2020-06-100001434265gmab:TripleaRatingMemberifrs-full:CreditRiskMember2023-12-310001434265gmab:TripleaRatingMemberifrs-full:CreditRiskMember2022-12-310001434265gmab:MartineVanVugtMember2023-01-012023-12-310001434265gmab:ExecutiveManagerTahamtanAhmadiMember2023-01-012023-12-310001434265gmab:ExecutiveManagerJudithKlimovskyMember2023-01-012023-12-310001434265gmab:ExecutiveManagerJanVanDeWinkelMember2023-01-012023-12-310001434265gmab:ExecutiveManagerAnthonyPaganoMember2023-01-012023-12-310001434265gmab:ExecutiveManagerAnthonyManciniMember2023-01-012023-12-310001434265gmab:ChristopherCozicMember2023-01-012023-12-310001434265gmab:BirgitteStephensenMember2023-01-012023-12-310001434265gmab:ExecutiveManagerTahamtanAhmadiMember2022-01-012022-12-310001434265gmab:ExecutiveManagerJudithKlimovskyMember2022-01-012022-12-310001434265gmab:ExecutiveManagerJanVanDeWinkelMember2022-01-012022-12-310001434265gmab:ExecutiveManagerAnthonyPaganoMember2022-01-012022-12-310001434265gmab:ExecutiveManagerAnthonyManciniMember2022-01-012022-12-310001434265gmab:ExecutiveManagementMember2022-01-012022-12-310001434265gmab:ExecutiveManagerTahamtanAhmadiMember2021-01-012021-12-310001434265gmab:ExecutiveManagerJudithKlimovskyMember2021-01-012021-12-310001434265gmab:ExecutiveManagerJanVanDeWinkelMember2021-01-012021-12-310001434265gmab:ExecutiveManagerAnthonyPaganoMember2021-01-012021-12-310001434265gmab:ExecutiveManagerAnthonyManciniMember2021-01-012021-12-310001434265gmab:ExecutiveManagementMember2021-01-012021-12-310001434265currency:DKK2023-01-012023-12-310001434265ifrs-full:RetainedEarningsMember2023-01-012023-12-310001434265ifrs-full:RetainedEarningsMember2022-01-012022-12-310001434265ifrs-full:RetainedEarningsMember2021-01-012021-12-310001434265gmab:ExecutiveManagementMemberifrs-full:TopOfRangeMember2023-01-012023-12-310001434265gmab:ExecutiveManagementMemberifrs-full:TopOfRangeMember2022-01-012022-12-310001434265gmab:ExecutiveManagementMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001434265gmab:RestrictedStockUnitsRSUsMember2019-12-012021-02-280001434265ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2023-12-310001434265ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2023-12-310001434265ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2023-12-310001434265ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2023-12-310001434265ifrs-full:LaterThanFiveYearsMember2023-12-310001434265gmab:UsGovernmentBondsAndTreasuryBillsMember2023-12-310001434265gmab:UsdPortfolioMember2023-12-310001434265gmab:UkGovernmentBondsAndTreasuryBillsMember2023-12-310001434265gmab:OtherMarketableSecuritiesMember2023-12-310001434265gmab:KingdomOfDenmarkBondsAndTreasuryBillsMember2023-12-310001434265gmab:IfrsCommercialPaperMember2023-12-310001434265gmab:EuropeanGovernmentBondsAndTreasuryBillsMember2023-12-310001434265gmab:DkkPortfolioMember2023-12-310001434265gmab:DanishMortgageBackedSecuritiesMember2023-12-310001434265gmab:CorporateBondsMember2023-12-310001434265ifrs-full:NotLaterThanOneYearMember2022-12-310001434265ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2022-12-310001434265ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-12-310001434265ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2022-12-310001434265ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2022-12-310001434265ifrs-full:LaterThanFiveYearsMember2022-12-310001434265gmab:UsGovernmentBondsAndTreasuryBillsMember2022-12-310001434265gmab:UsdPortfolioMember2022-12-310001434265gmab:UkGovernmentBondsAndTreasuryBillsMember2022-12-310001434265gmab:OtherMarketableSecuritiesMember2022-12-310001434265gmab:KingdomOfDenmarkBondsAndTreasuryBillsMember2022-12-310001434265gmab:IfrsCommercialPaperMember2022-12-310001434265gmab:EuropeanGovernmentBondsAndTreasuryBillsMember2022-12-310001434265gmab:DkkPortfolioMember2022-12-310001434265gmab:DanishMortgageBackedSecuritiesMember2022-12-310001434265gmab:CorporateBondsMember2022-12-310001434265gmab:CurevacCollaborationMember2023-01-012023-12-310001434265gmab:CurevacCollaborationMember2022-01-012022-12-310001434265gmab:CurevacCollaborationMember2021-01-012021-12-310001434265ifrs-full:TopOfRangeMember2022-01-012022-12-310001434265ifrs-full:BottomOfRangeMember2022-01-012022-12-310001434265ifrs-full:TopOfRangeMember2021-01-012021-12-310001434265ifrs-full:BottomOfRangeMember2021-01-012021-12-310001434265currency:USD2023-01-012023-12-310001434265currency:USD2022-01-012022-12-310001434265ifrs-full:SharePremiumMember2020-12-310001434265ifrs-full:RetainedEarningsMember2020-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001434265ifrs-full:IssuedCapitalMember2020-12-3100014342652020-12-310001434265gmab:ExecutiveManagementMember2023-01-012023-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember2022-01-012022-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMembergmab:EquipmentFurnitureAndFixturesMember2022-01-012022-12-310001434265ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-12-310001434265ifrs-full:IntangibleAssetsOtherThanGoodwillMember2023-01-012023-12-310001434265ifrs-full:IntangibleAssetsOtherThanGoodwillMember2022-01-012022-12-310001434265ifrs-full:IntangibleAssetsOtherThanGoodwillMember2021-01-012021-12-310001434265gmab:PropertyAndEquipmentMember2023-01-012023-12-310001434265gmab:PropertyAndEquipmentMember2022-01-012022-12-310001434265gmab:PropertyAndEquipmentMember2021-01-012021-12-310001434265gmab:AgreementsWithAbbvieMember2023-12-310001434265gmab:AgreementsWithAbbvieMember2022-12-310001434265gmab:AgreementsWithAbbvieMember2021-12-310001434265ifrs-full:TopOfRangeMember2023-01-012023-12-310001434265ifrs-full:BottomOfRangeMember2023-01-012023-12-310001434265ifrs-full:TreasurySharesMember2023-01-012023-12-310001434265ifrs-full:TreasurySharesMember2022-01-012022-12-310001434265ifrs-full:TreasurySharesMember2021-01-012021-12-310001434265ifrs-full:PreviouslyStatedMember2022-12-310001434265ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember2022-12-310001434265ifrs-full:PreviouslyStatedMember2021-12-310001434265ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember2021-12-3100014342652021-12-310001434265gmab:AgreementsWithAbbvieMemberifrs-full:PerformanceObligationsSatisfiedOverTimeMember2020-06-102020-06-100001434265gmab:AgreementsWithAbbvieMemberifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2020-06-102020-06-100001434265gmab:AgreementsWithAbbvieMember2020-06-102020-06-100001434265gmab:AgreementsWithBointechMember2023-01-012023-12-310001434265gmab:AgreementWithJanssenDuobodyMemberifrs-full:TopOfRangeMember2023-01-012023-12-310001434265gmab:AgreementWithJanssenDuobodyMemberifrs-full:BottomOfRangeMember2023-01-012023-12-310001434265gmab:AgreementsWithAbbvieMembergmab:CountriesOutsideUnitedStatesAndJapanMemberifrs-full:TopOfRangeMember2020-06-102020-06-100001434265gmab:AgreementsWithAbbvieMembergmab:CountriesOutsideUnitedStatesAndJapanMemberifrs-full:BottomOfRangeMember2020-06-102020-06-100001434265gmab:AgreementsWithAbbvieMemberifrs-full:TopOfRangeMember2020-06-102020-06-100001434265gmab:AgreementsWithAbbvieMemberifrs-full:BottomOfRangeMember2020-06-102020-06-100001434265gmab:AgreementsWithJanssenMemberifrs-full:TopOfRangeMember2012-01-012012-12-310001434265gmab:AgreementsWithJanssenMemberifrs-full:BottomOfRangeMember2012-01-012012-12-310001434265gmab:AgreementsWithJanssenMember2023-01-012023-12-310001434265gmab:AgreementWithJanssenDuobodyMember2023-01-012023-12-310001434265gmab:AgreementsWithRocheMember2001-05-312001-05-310001434265gmab:AgreementsWithNovartisMember2023-01-012023-12-310001434265gmab:AgreementsWithSeagenMember2020-10-012020-10-3100014342652023-12-3100014342652022-12-310001434265gmab:AgreementsWithSeagenMember2021-09-012021-09-300001434265ifrs-full:PreviouslyStatedMember2022-01-012022-12-310001434265ifrs-full:PreviouslyStatedMember2021-01-012021-12-310001434265gmab:TakahiroHamataniMember2023-01-012023-12-310001434265gmab:MartinSchultzMember2023-01-012023-12-310001434265gmab:ElizabethOfarrellMember2023-01-012023-12-310001434265gmab:BoardOfDirectorsMember2023-01-012023-12-310001434265gmab:BoardOfDirectorRolfHoffmannMember2023-01-012023-12-310001434265gmab:BoardOfDirectorPernilleErenbjergMember2023-01-012023-12-310001434265gmab:BoardOfDirectorPaoloPaolettiMember2023-01-012023-12-310001434265gmab:BoardOfDirectorMijkeZachariasseMember2023-01-012023-12-310001434265gmab:BoardOfDirectorDeirdreP.ConnellyMember2023-01-012023-12-310001434265gmab:BoardOfDirectorAndersGerselPedersenMember2023-01-012023-12-310001434265gmab:TakahiroHamataniMember2022-01-012022-12-310001434265gmab:MartinSchultzMember2022-01-012022-12-310001434265gmab:ElizabethOfarrellMember2022-01-012022-12-310001434265gmab:BoardOfDirectorsMember2022-01-012022-12-310001434265gmab:BoardOfDirectorRolfHoffmannMember2022-01-012022-12-310001434265gmab:BoardOfDirectorPeterStormKristensenMember2022-01-012022-12-310001434265gmab:BoardOfDirectorPernilleErenbjergMember2022-01-012022-12-310001434265gmab:BoardOfDirectorPaoloPaolettiMember2022-01-012022-12-310001434265gmab:BoardOfDirectorMijkeZachariasseMember2022-01-012022-12-310001434265gmab:BoardOfDirectorDeirdreP.ConnellyMember2022-01-012022-12-310001434265gmab:BoardOfDirectorDanielBrunoMember2022-01-012022-12-310001434265gmab:BoardOfDirectorAndersGerselPedersenMember2022-01-012022-12-310001434265gmab:BoardOfDirectorsMember2021-01-012021-12-310001434265gmab:BoardOfDirectorRolfHoffmannMember2021-01-012021-12-310001434265gmab:BoardOfDirectorPeterStormKristensenMember2021-01-012021-12-310001434265gmab:BoardOfDirectorPernilleErenbjergMember2021-01-012021-12-310001434265gmab:BoardOfDirectorPaoloPaolettiMember2021-01-012021-12-310001434265gmab:BoardOfDirectorMijkeZachariasseMember2021-01-012021-12-310001434265gmab:BoardOfDirectorJonathanPeacockMember2021-01-012021-12-310001434265gmab:BoardOfDirectorDeirdreP.ConnellyMember2021-01-012021-12-310001434265gmab:BoardOfDirectorDanielBrunoMember2021-01-012021-12-310001434265gmab:BoardOfDirectorAndersGerselPedersenMember2021-01-012021-12-310001434265ifrs-full:CreditRiskMember2023-12-310001434265ifrs-full:CreditRiskMember2022-12-3100014342652022-01-012022-12-3100014342652021-01-012021-12-3100014342652023-01-012023-12-31iso4217:DKKiso4217:USDiso4217:DKKxbrli:sharesxbrli:pureiso4217:USDiso4217:DKKxbrli:sharesgmab:itemgmab:productgmab:Votegmab:EquityInstruments
GENMAB 2023 ANNUAL REPORT
| Management's Review | |
| Our 2030 Vision | 2 |
| Chair's Statement | 2 |
| Letter from the CEO | 3 |
| 2023 at a Glance | 5 |
| Consolidated Key Figures | 6 |
| 2024 Outlook | 9 |
| Our Strategy | 11 |
| Who We Are | 13 |
| Business Model | 15 |
| Research and Development Capabili ties | 15 |
| Bringing Our Own Innovative Medicines to Patients | 16 |
| Antibody Discovery and Development | 18 |
| Products and Technologies | 18 |
| Corporate Social Responsibility and Sustainability Commitments | 39 |
| Genmab's Task Force on Climate-related Financial Disclosures | 41 |
| Stakeholder Engagement | 45 |
| Human Capital Management | 46 |
| Financial Review | 48 |
| Risk Management | 60 |
| Enterprise Risk Management | 65 |
| Corporate Governance | 66 |
| Board of Directors | 68 |
| Executive Management | 72 |
| Shareholders and Share Information | 75 |
| FINANCIAL STATEMENTS FOR THE GENMAB GROUP | 79 |
| FINANCIAL STATEMENTS FOR THE PARENT COMPANY | 137 |
| DIRECTORS' AND MANAGEMENT'S STATEMENT ON THE ANNUAL REPORT | 157 |
| INDEPENDENT AUDITOR'S REPORT S | 158 |
| Other information | 162 |
| Glossary | 162 |
| Forward Looking Statement | 164 |
| Contact Information | 165 |
2023 Corporate Responsibility Report
2023 Corporate Governance Report
2023 Compensation Report
Our Corporate Responsibility, Corporate Governance and Compensation Reports for 2023 can be found on our website, Genmab.com.
GENMAB 2023 ANNUAL REPORT
By 2030, our KYSO (knock-your-socks-off) antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.
Our Core Purpose, Supporting Our 2030 Vision
Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics.
At Genmab, we strive to be our best for patients with cancer and other serious diseases and the stakeholders we serve. Our innovators and forward-thinkers work collaboratively to pioneer new antibody-based medicines and technologies, to inspire great ideas, and to support a shared vision of making a difference in the lives of patients. Genmab has grown our unstoppable team at all levels to create life-altering medicines, and to benefit our patients, employees, and the communities where we live and work.
Genmab hit a major milestone in 2023, reaching 2,000 team members internationally. This exciting landmark is evidence of our hard work and laser-focus to power antibody medicines. Throughout our growth, we ensured that our teams act on our values: innovating, bringing great minds, cultures, and perspectives into the conversation, remaining patient-centric, and supporting our communities.
In our efforts to have a positive impact for patients with cancer and other serious diseases, our team has deepened our focus on patient advocacy this year. The patient perspective is paramount to innovation in research and development (R&D) and scientific advancement. Genmab's commitment to creating a meaningful difference is exemplified through our unwavering focus on understanding the unique experiences and stories that shape the patient journey. In 2023, Genmab colleagues participated in events that demonstrate our commitment and put our words into action. The Light the Night walk, a fundraising event supporting The Leukemia & Lymphoma Society that rallies U.S. local communities to honor and support those touched by cancer, is one shining example. With our increasing footprint, we had engagement in 16 communities in 12 states across the U.S.. By placing the patient at the forefront, Genmab not only aims to bring patient-centered treatments to market, but also seeks to address the practical and emotional aspects vital to the well-being of the patient communities we serve.
Genmab is preparing for upcoming global reporting requirements and other local reporting legislation that will guide our sustainability strategy in 2024 and beyond, including the EU's Corporate Sustainability Reporting Directive (CSRD) and the U.S. Securities and Exchange Commission's Climate-Related Disclosures.
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 2/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
EXPERIENCED LEADERSHIP
We operate from a core set of values that underpins every decision we make. Our commitment to operating with integrity requires us to keep our minds focused on the future while remaining rooted in science and inspired by patients. Genmab strengthened our Executive Management in 2023 appointing Martine J. van Vugt, Ph.D. as our first Chief Strategy Officer. Beginning her professional career at Genmab in 2001, Dr. van Vugt has been active in business development since 2011.
In 2023, our Board of Directors continued to provide governance, guidance and dedicated leadership. Comprised of experts in their fields, the Board of Directors has supported organizational growth initiatives, driven global change, and contributed value across Genmab.
On behalf of the Board of Directors, I would like to thank Genmab's dedicated team members, CEO Jan van de Winkel and the entire global leadership team for their inspiration and extraordinary leadership as well as our shareholders for your continued support.
New horizons inspired by our accomplishments
2023 was a standout year for Genmab. For many years our team was a small one, but it was dedicated - dedicated to the idea that Genmab's innovations could someday make a difference in the lives of people with cancer.
That someday is today.
There are now eight approved medicines based on Genmab's innovation and antibody expertise.
Epcoritamab became our second product on the market, approved as EPKINLY in the U.S. and Japan and TEPKINLY in Europe. With EPKINLY we are, for the first time in our history, the commercial lead in both the U.S. and Japan. Looking to the future, in 2024 we anticipate additional approvals in a new indication and the start of multiple Phase 3 trials with the goal of moving into earlier lines of therapy. This expansion reflects the robust clinical development program across B-cell malignancies that we're continually developing with our partners at AbbVie Inc. (AbbVie). However, epcoritamab is only one of our exciting programs.
We also saw very good progress with Tivdak (tisotumab vedotin-tftv) this year. With the positive results from both the confirmatory innovaTV 301 study in cervical cancer and data in head and neck cancer from the innovaTV 207 study, tisotumab vedotin has cleared our very high bar for continued investment in development. We are very pleased with our plans to actively engage with health authorities on the next steps for tisotumab vedotin in both of these indications, along with our partner, Pfizer Inc. (Pfizer).
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 3/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
Acasunlimab (GEN1046 (BNT311, DuoBody -PD-L1x4-1BB), developed with BioNTech SE (BioNTech), has also shown promise in second line non-small cell lung cancer (NSCLC). Based on preliminary data, we and our partner, BioNTech, are working with health authorities on next steps for the program and we look forward to presenting the data at a medical conference in 2024. Beyond acasunlimab, our successful partnership with BioNTech has also provided us with multiple other promising programs including the clinical-stage programs GEN1042 (BNT312, DuoBody-CD40x4-1BB), which generated encouraging data in multiple solid tumors in 2023, GEN1053 (BNT313, HexaBody -CD27) and next in the clinic, GEN1059 (BNT314, DuoBody-EpCAMx4-1BB) and GEN1055 (BNT315, HexaBody-OX40).
Two other pipeline programs that advanced in 2023 are GEN1047 or DuoBody-CD3xB7H4 and GEN3017 or DuoBody-CD3xCD30. The Phase 1/2 trial of GEN1047 is currently in the dose expansion phase, an important step in progressing our CD3-based bispecific platform in solid tumors. GEN3017 started recruitment for a first-in-human clinical trial in hematological malignancies.
Our DuoBody partnership with Janssen Biotech, Inc. (Janssen) has continued to be fruitful. Three approved medicines have now come from this collaboration: RYBREVANT (amivantamab), TECVAYLI (teclistamab) and TALVEY (talquetamab), the latter of which was approved in both the U.S. and Europe in 2023. We believe the success of these bispecific programs highlights the potential of our innovative DuoBody technology and we look forward to seeing their continued development.
When Genmab made a strategic commitment to focus on our core competencies in the development of antibody therapies, we were focused specifically on medicines for cancer. However, our knowledge of specific immunological pathways and access to unique next-generation antibody formats that we harnessed to fight cancer can also be applied to create therapies for immune-mediated and inflammatory diseases (I&I). As such, this year we updated our vision that by 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.
Including indications beyond oncology made perfect sense as Genmab-created antibodies now marketed by our partners are approved in areas such as multiple sclerosis and thyroid eye disease. To this end in 2023 we partnered with argenx SE (argenx), giving us the opportunity to explore patients' needs in oncology as well as I&I.
A proven way forward
The approval of our first two Genmab co-owned therapies established a way forward; a roadmap to explore and bring to patients novel treatments for cancer and other diseases. We have focused our attention to the present, and our eyes to the future; a future in which our KYSO antibody medicines can fundamentally transform the lives of patients for the better. We believe we will continue to bring hope with our proprietary technologies and antibody-based products. As such, our philosophy of strategic and disciplined development and growth has served us well and we plan to continue doing just that.
As we successfully grew our promising portfolio and built our teams, the time came in 2023 to build a new, larger headquarters site in Copenhagen. This state-of-the-art building marks how far we've come as a company and houses 500 team members, all pulling together towards a common goal under the same roof. Our Global R&D Center also expanded with the opening of the Accelerator, an iconic multi-tenant building nestled in the heart of the Utrecht Science Park, now home to the efforts of many more of our antibody experts and scientists.
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 4/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
I am confident that in 2024, we will continue this momentum on our journey to become a biotech innovation powerhouse. Our success is only possible because of our talented and unstoppable team, the patients who participate in our clinical trials and their care partners, the investigators who run these trials, our partners who believe in the power of our cutting-edge technologies and antibody therapies, our supportive Board of Directors, and our shareholders who believe in our vision. Together we are creating a KYSO future. I thank you for your continued support.
Jan van de Winkel, Ph.D.
President & Chief Executive Officer
1 In March 2023, Genmab's partner Seagen Inc. (Seagen) announced that it would be acquired by Pfizer. Pfizer closed the acquisition of Seagen on December 14, 2023. All references to Seagen in this document have been changed to Pfizer.
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 5/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
* See Note 1.4 in the consolidated financial statements for details regarding the revision of prior period financial statements.
** 2020 Operating Profit impacted by one-time AbbVie upfront payment.
Consolidated Key Figures
| (DKK million) | |||||||||
| Income Statement | 2019* | 2020* | 2021* | 2022* | 2023 | ||||
| Revenue | 5,351 | 10,088 | 8,417 | 14,505 | 16,474 | ||||
| Cost of product sales | - | - | - | - | (226) | ||||
| Research and development expenses | (2,386) | (3,137) | (4,181) | (5,562) | (7,630) | ||||
| Selling, general and administrative expenses | (342) | (661) | (1,283) | (2,676) | (3,297) | ||||
| Operating expenses | (2,728) | (3,798) | (5,464) | (8,238) | (10,927) | ||||
| Operating profit | 2,623 | 6,290 | 2,953 | 6,267 | 5,321 | ||||
| Net financial items | 221 | (409) | 965 | 678 | 316 | ||||
| Net profit | 2,151 | 4,740 | 2,957 | 5,452 | 4,352 | ||||
| Balance Sheet | |||||||||
| Marketable securities | 7,419 | 8,819 | 10,381 | 12,431 | 13,268 | ||||
| Cash and cash equivalents | 3,552 | 7,260 | 8,957 | 9,893 | 14,867 | ||||
| Total non-current assets | 1,183 | 2,352 | 1,891 | 1,901 | 2,150 | ||||
| Total assets | 15,124 | 21,105 | 24,538 | 30,119 | 35,289 | ||||
| Shareholders' equity | 14,028 | 19,083 | 22,107 | 27,282 | 31,610 | ||||
| Share capital | 65 | 66 | 66 | 66 | 66 | ||||
| Cash Flow Statement | |||||||||
| Cash flow from operating activities | 1,326 | 6,433 | 2,228 | 3,912 | 7,380 | ||||
| Cash flow from investing activities | (1,983) | (2,351) | (961) | (2,761) | (1,282) | ||||
| Cash flow from financing activities | 3,660 | 71 | (420) | (789) | (606) | ||||
| Investments in intangible assets | (32) | - | - | - | (10) | ||||
| Investments in tangible assets | (79) | (307) | (252) | (317) | (366) | ||||
| Financial Ratios and Other Information | |||||||||
| Basic net profit per share | 34.16 | 72.72 | 45.22 | 83.38 | 66.64 | ||||
| Diluted net profit per share | 33.80 | 71.94 | 44.77 | 82.59 | 66.02 | ||||
| Year-end share market price | 1,481.50 | 2,463.00 | 2,630.00 | 2,941.00 | 2,155.00 | ||||
| Price / book value | 6.86 | 8.52 | 7.85 | 7.11 | 4.50 | ||||
| Shareholders' equity per share | 215.82 | 289.14 | 334.95 | 413.36 | 478.94 | ||||
| Equity ratio | 93% | 90% | 90% | 91% | 90% | ||||
| Shares outstanding | 65,074,502 | 65,545,748 | 65,718,456 | 65,961,573 | 66,074,535 | ||||
| Average number of employees (FTE)** | 471 | 656 | 1,022 | 1,460 | 2,011 | ||||
| Number of employees (FTE) at year-end | 548 | 781 | 1,212 | 1,660 | 2,204 |
* See Note 1.4 in the consolidated financial statements for details regarding the revision of prior period financial statements.
** Full-time equivalent (FTE) or team member
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 6/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
* See Note 1.4 in the consolidated financial statements for details regarding the revision of prior period financial statements.
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 7/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 8/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
| (DKK millions) | 2023 Actual Result | 2024 Guidance | 2024 Guidance Mid-Point | 2023 Growth % | 2024 Growth %* |
| Revenue | 16,474 | 18,700 - 20,500 | 19,600 | 14% | 19% |
| Royalties | 13,705 | 15,600 - 16,700 | 16,150 | 18% | 18% |
| Net product sales/Collaboration revenue ** | 728 | 1,700 - 2,200 | 1,950 | 231% | 168% |
| Milestones/Reimbursement revenue | 2,041 | 1,400 - 1,600 | 1,500 | -24% | -27% |
| Gross profit | 16,248 | 18,000 - 19,500 | 18,750 | 12% | 15% |
| Operating expenses | (10,927) | (12,400) - (13,400) | (12,900) | 33% | 18% |
| Operating profit | 5,321 | 4,600 - 7,100 | 5,850 | -15% | 10% |
*Mid-point of guidance range
**Net product sales and collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak (Genmab's share of gross profits) in the U.S. Collaboration revenue excludes one-off payment in 2022 from Pfizer of approximately USD 15 million (DKK 112 million) related to the sublicense of rights to develop and commercialize tisotumab vedotin in China to Zai Lab Hong Kong. This amount is included in Milestone/Reimbursement revenue for this presentation.
Genmab expects its 2024 revenue to be in the range of DKK 18.7 - 20.5 billion, compared to DKK 16.5 billion in 2023. Our revenue in 2023 was driven primarily by DARZALEX (daratumumab) royalties due to the continued strong growth of DARZALEX net sales partially offset by negative exchange rate movements between the USD and DKK and negative impact of applying the DARZALEX contractual annual Currency Hedge Rate.
Genmab's projected revenue growth for 2024 is driven by higher royalties, net product sales and collaboration revenue. Royalty growth relates mainly to DARZALEX and Kesimpta (ofatumumab) net sales growth. Net product sales and collaboration revenue growth driven by strong performance for both Tivdak and EPKINLY. Net product sales and collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak (50% gross profit share) in the U.S.
Genmab's projected revenue for 2024 primarily consists of DARZALEX royalties of DKK 12.6 - 13.3 billion. Such royalties are based on estimated DARZALEX 2024 net sales of USD 10.9 - 11.5 billion compared to actual net sales in 2023 of approximately USD 9.7 billion. DARZALEX royalties are partly offset by Genmab's share of Janssen's royalty payments to Halozyme Therapeutics, Inc. (Halozyme) in connection with subcutaneous (SC) net sales as well as royalty reduction in countries and territories where there are no Genmab patents.
The remainder of Genmab's revenue consists of royalties from Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY and TEPKINLY, net product sales and collaboration revenue from EPKINLY and Tivdak, reimbursement revenue and milestones.
Genmab anticipates its 2024 operating expenses to be in the range of DKK 12.4 - 13.4 billion, compared to DKK 10.9 billion in 2023. The growth in operating expenses is to support Genmab's continued portfolio advancement and investing for future product launches, including epcoritamab.
Genmab expects its operating profit to be in the range of DKK 4.6 - 7.1 billion in 2024, compared to DKK 5.3 billion in 2023.
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 9/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
Outlook: Risks and Assumptions
In addition to factors already mentioned, the estimates above are subject to change due to numerous reasons, including but not limited to, the achievement of certain milestones associated with Genmab's collaboration agreements; the timing and variation of development activities (including activities carried out by Genmab's collaboration partners) and related income and costs; DARZALEX, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY and TEPKINLY net sales and royalties paid to Genmab; changing rates of inflation; and currency exchange rates (the 2024 guidance assumes a USD / DKK exchange rate of 6.8). The financial guidance assumes that no significant new agreements are entered into during 2024 that could materially affect the results.
The factors discussed above, as well as other factors that are currently unforeseeable, may result in further and other unforeseen material adverse impacts on Genmab's business and financial performance, including on the sales of Tivdak and EPKINLY, and on the net sales of DARZALEX, Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY and TEPKINLY by Genmab's collaboration partners and on Genmab's royalties, collaboration revenue and milestone revenue therefrom.
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 10/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
| Tokyo, JapanTokyo, Japanur Strategy | |||
| Our Strategy | |||
| Business Strategy | Priorities in 2023 | Priorities for 2024 | Link to Risk |
| Build a profitable and successful biotech Maintain a flexible and capital-efficient model Maximize relationships with partners Retain ownership of select products | Invest in our people and culture Further scale organization aligned with differentiated antibody product portfolio growth and future launches Become a leading integrated biotech innovation powerhouse Use solid financial base to grow and broaden antibody product and technology portfolio | Invest in our people and culture Further scale organization aligned with differentiated antibody product portfolio growth and future launches Become a leading integrated biotech innovation powerhouse Use solid financial base to grow and broaden antibody product and technology portfolio | Please refer to the risks included in this Annual Report . |
| Focus on core competence I dentify the best disease targets Develop unique first-in-class or best-in-class antibodies Develop next-generation technologies | Build a world-class differentiated pipeline Acasunlimab (GEN1046/BNT311, DuoBody-PD-L1x4-1BB) 1 o Establish proof of concept data in solid tumor indication GEN1042 (BNT312, DuoBody-CD40x4-1BB) 1 o Establish efficacy and safety data in solid tumor indication o Progress towards late-stage clinical development Expand and advance proprietary clinical product portfolio | Build world-class differentiated pipeline Acasunlimab ( GEN1046/BNT311, DuoBody-PD-L1x4-1BB) 1 o Initiate Phase 3 study (2L NSCLC) GEN1042 (DuoBody-CD40x4-1BB ) 1 o Phase 2 data and determine next steps Expand and advance proprietary product portfolio | Please refer to the risks included in this Annual Report . |
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 11/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
| Turn science into medicine Create differentiated antibody therapeutics with significant commercial potential | Bring our own medicines to patients Epcoritamab 2 o Launch in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) o Submit a supplemental Biologics License Application (sBLA) o Broaden clinical development program Tivdak 3 o Progress successful uptake in second line (2L)+ recurrent or metastatic cervical cancer patients Progress clinical development program | Bring our own medicines to patients & expand our markets EPKINLY o Initiate three Phase 3 trials o Expand label to include relapsed/refractory FL Tivdak o Initiate Phase 3 study in head and neck Execute successful launches and growth in key markets | Please refer to the risks included in this Annual Report . |
| CSR Strategy | Priorities in 2023 | Priorities for 2024 | Link to Risk |
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 12/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
1. Co-development with BioNTech; 2. Co-development with AbbVie; 3. Co-development with Pfizer
In our quest to turn science into medicine, we use these guideposts to transform the future of cancer treatment:
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 13/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
Genmab's Growing Organization and Presence
Our Key Accomplishments
Each of our achievements stands as evidence of our unyielding determination, including:
| Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 05 |
| Carl Jacobsens Vej 30 | Page 14/165 | |
| 2500 Valby, Denmark | www.genmab.com | CVR no. 2102 3884 |
GENMAB 2023 ANNUAL REPORT
At Genmab, we have built a profitable and successful biotech that creates value for our stakeholders.
Our Strengths and Differentiators
Building a Fully Integrated Biotech Innovation Powerhouse
Research: track record of success and investing for tomorrow
Development: scaling up capabilities to expand from early- to late-stage development
Commercialization: building the next step in our evolution
Enabling functions: supporting growth and managing risk
Research and Development Capabilities
At Genmab, we are inspired by nature and understand how antibodies work. We are deeply knowledgeable about antibody biology and our scientists harness this expertise to create and develop differentiated investigational antibody medicines. We utilize a sophisticated and highly automated process to efficiently generate, select, produce, and evaluate human antibody-based products. Our teams have established a fully integrated R&D enterprise and streamlined process to coordinate the activities of antibody product discovery, preclinical testing, manufacturing, clinical trial design and execution, and regulatory submissions across Genmab's international operations. We have expanded our scientific focus to use data science and artificial intelligence to aid in the discovery of new targets and biomarkers and bolster our in-depth precision medicine and translational laboratory capabilities. Through our expertise in antibody drug development, we pioneer technologies that allow us to create differentiated and potentially first-in-class or best-in-class investigational medicines with the potential to improve patients' lives. Our antibody expertise has enabled us to create our cutting-edge technology platforms: DuoBody, HexaBody, DuoHexaBody and HexElect .
Sustainable and State-of-the-Art Facilities